NewsRx

Search our medical news database

Patents

Broad patent granted for use of immune stimulatory CpG oligonucleotides

Published in Vaccine Weekly, December 24th, 2003

Coley Pharmaceutical Group announced that the U.S. Patent and Trademark Office has issued U. S. Patent 6,653,292 titled "Methods Of Treating Cancer Using Immunostimulatory Oligonucleotides."

The patent broadly protects the use of immune stimulatory CpG oligonucleotides (CpG TLR9 agonists) to treat or prevent cancer or to enhance multimodal cancer treatment regimens.

The patent covers a family of synthetic oligonucleotides that contain CpG motifs. Cancer treatment applications protected by this patent include CpG TLR9 agonist monotherapy and combination therapies where CpG TLR9 agonists are used to enhance the anticancer activity of other regimens,...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook